BT
BTMD.US biote Corp
- Market cap
- USD 33.9M
- P/E
- -
- P/B
- 2.96x
- ROE
- -
- Dividend yield
- 5.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BTMD.US undervalued?
Graham numberThe Graham number of biote Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
biote Corp fundamental analysis
No fundamental analysis for biote Corp yet.
biote Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space com…
Full company profilebiote Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
biote Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 110M | 117M | 139M | 165M | 185M | 197M | 192M | 177M |
| Gross Profit | 66.4M | 71.6M | 90.6M | 110M | 127M | 139M | 137M | 98.5M |
| Operating Income | 23.5M | 31.8M | 34.6M | -60.7M | 28.7M | 31.6M | 35.6M | 2.86M |
| EBITDA | 24.3M | 32.9M | 36.0M | 7.96M | 41.7M | 15.6M | 52.2M | 9.09M |
| Net Income | 21.3M | 29.2M | 32.6M | -969K | 3.32M | 3.16M | 27.0M | -5.17M |
| EPS | 2.81 | 3.85 | 4.31 | -0.12 | 0.13 | 0.09 | 0.74 | -0.19 |
| Balance Sheet | ||||||||
| Total Assets | 23.9M | 32.6M | 54.3M | 112M | 155M | 122M | 108M | 102M |
| Total Liabilities | 56.8M | 49.7M | 50.2M | 170M | 192M | 225M | 158M | 159M |
| Shareholders' Equity | -32.9M | -17.1M | 4.13M | -44.5M | -29.4M | -106M | -58.5M | -65.3M |
| Cash & Short-term Investments | 10.5M | 17.2M | 26.8M | 79.2M | 89.0M | 39.3M | 24.1M | 8.85M |
| Total Debt | 47.1M | 42.4M | 37.3M | 120M | 115M | 111M | 110M | 128M |
| Cash Flow | ||||||||
| Operating Cash Flow | 25.4M | 26.4M | 33.7M | -9.16M | 26.9M | 45.2M | 35.2M | 8.55M |
| Capital Expenditure | 1.67M | 1.39M | 3.81M | 1.84M | 2.71M | 6.43M | 5.02M | 7.33M |
| Free Cash Flow | 23.7M | 25.0M | 29.9M | -11.0M | 24.2M | 38.8M | 30.2M | 1.22M |
| Ratios | ||||||||
| ROE | - | - | 790.8% | - | - | - | - | - |
| ROA | 89.1% | 89.5% | 60.0% | -0.9% | 2.1% | 2.6% | 25.1% | -5.1% |
| Net Profit Margin | 19.4% | 25.0% | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% | -2.9% |
| Debt to Equity | - | - | 9.05x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
biote Corp dividends
- Dividend yield
- 5.10%
- Forward dividend
- -
- Payout ratio
- 6.4%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.73M | 0.05 | 6.4% |
| 2024 | USD 4.74M | 0.14 | 150.3% |
| 2023 | USD 8.69M | 0.34 | 262.2% |
| 2022 | USD 12.9M | 1.60 | - |
| 2021 | USD 11.4M | 1.51 | 35.0% |
| 2020 | USD 13.3M | 1.76 | 45.7% |
| 2019 | USD 56.6M | 7.48 | 266.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns biote Corp
- Insiders 19.85%
- Institutions 55.85%
- Public & others 24.30%
- Shares outstanding 27.0M
- Free float 15.6M
Top funds holding BTMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 830K | 2.89% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 165K | 0.58% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 124K | 0.43% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 113K | 0.39% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 80.6K | 0.28% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 59.0K | 0.21% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 40.3K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 34.9K | 0.12% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 34.1K | 0.12% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 13.0K | 0.05% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 6.66K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 6.45K | 0.02% | 0.00% | Sep 2026 |
| JNL/DFA US Small Cap A | 6.00K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 5.88K | 0.02% | 0.00% | Sep 2026 |
| Dimensional World Equity GBP Acc | 4.94K | 0.02% | -0.22% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 4.17K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sm Company EUR Acc | 3.85K | 0.01% | -0.31% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 3.82K | 0.01% | -0.29% | Sep 2026 |
Top institutions holding BTMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| 325 Capital LLC | 4.55M | 15.86% | 0.00% | Jun 2026 |
| Bandera Partners LLC | 2.07M | 7.20% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.10M | 3.85% | -1.00% | Jun 2026 |
| Acadian Asset Management LLC | 625K | 2.18% | -10.38% | Jun 2026 |
| Millennium Management LLC | 436K | 1.52% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 424K | 1.48% | -1.85% | Sep 2026 |
| BlackRock Inc | 366K | 1.28% | -78.96% | Jun 2026 |
| Citadel Advisors Llc | 301K | 1.05% | 0.00% | Jun 2026 |
| Rice Hall James & Associates, LLC | 263K | 0.92% | +5.13% | Jun 2026 |
| Geode Capital Management, LLC | 260K | 0.91% | -57.69% | Jun 2026 |
| Jane Street Group LLC | 253K | 0.88% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 252K | 0.88% | +368.92% | Jun 2026 |
| UBS Group AG | 244K | 0.85% | +849.25% | Jun 2026 |
| Renaissance Technologies Corp | 230K | 0.80% | -13.51% | Jun 2026 |
| The Goldman Sachs Group Inc | 215K | 0.75% | +114.08% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 169K | 0.59% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 154K | 0.54% | -18.22% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 143K | 0.50% | -9.02% | Jun 2026 |
| State Street Corp | 112K | 0.39% | -82.65% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 112K | 0.39% | +138.84% | Jun 2026 |
biote Corp company profile
- Company name
- biote Corp
- Ticker
- BTMD.US
- Exchange
- USA Stocks
- Listed since
- Apr 28, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 223
- Fiscal year end
- December
- Address
- 1875 W. Walnut Hill Ln #100, Irving, TX, United States, 75038
- Phone
- 844 604 1246
- Website
- biote.com
About biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
biote Corp management
9- Mr. Marc D. BeerExecutive Chairman · born 1965
- Mr. Robert C. PetersonInterim CEO, CFO & Chief Business Officer · born 1977
- Mr. John J. OlsenChief Information Officer · born 1957
- Mr. Dan MonicoGeneral Counsel
- Mr. Richard Kevin KeyChief Digital Officer · born 1971
- Mr. Jade BeutlerHead of Nutraceuticals · born 1964
- Dr. Cory Rice D.O.Chief Clinical Advisor & Member of Medical Advisory Board
- Mr. Joey LopesSVP of Strategy & Commercial Operations
- Dr. Komal Bajaj M.D., M.S.Chief Medical Officer